Menisor Xl

Isosorbide Mononitrate, the active ingredient in Menisor Xl, is a nitrate presented as an oral tablet for oral use. It is used to prevent and treat angina pectoris in adult patients who require anti‑anginal therapy.

GNH USA supplies Menisor Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isosorbide Mononitrate belongs to the nitrate class and is employed in the management of coronary artery disease‑related chest pain. - Angina pectoris: reduces the frequency and severity of anginal attacks. - Chronic stable angina: improves exercise tolerance and delays onset of pain. - Angina prophylaxis: prevents episodes of chest pain during physical or emotional stress.

Isosorbide Mononitrate may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate throbbing pain. - Dizziness or light‑headedness. - Flushing: warmth and redness of the skin. - Nausea or upset stomach. - Low blood pressure (hypotension). - Palpitations or rapid heartbeat.

Serious or Rare Side Effects: - Severe hypotension leading to syncope. - Acute myocardial infarction. - Allergic reactions such as rash, itching, or swelling. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Life‑threatening arrhythmias. - Unexplained chest pain despite therapy.

Before initiating therapy, clinicians should evaluate cardiovascular status and consider potential contraindications. - Assess cardiovascular health: ensure stable hemodynamics before use. - Avoid concurrent nitrates: risk of profound hypotension. - Do not combine with phosphodiesterase‑5 inhibitors: may cause severe blood pressure drops. - Monitor blood pressure regularly during dose adjustments. - Use with caution in elderly patients or those with hepatic impairment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Isosorbide Mononitrate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other nitrates (e.g., nitroglycerin): additive vasodilatory effect leading to severe hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of dangerous blood pressure reduction. - Potent vasodilators (e.g., hydralazine): may cause excessive blood pressure fall.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (beta‑blockers, ACE inhibitors): may enhance blood‑pressure‑lowering effect. - Diuretics: can increase risk of dehydration and hypotension. - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels of isosorbide mononitrate.